Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients

Abstract Introduction In addition to its role in the pathogenesis of migraine, calcitonin gene‐related peptide (CGRP) is implicated in the regulation of insulin secretion. However, there are limited data on the use of CGRP inhibitor monoclonal antibodies in individuals who are overweight/obese and t...

Full description

Bibliographic Details
Main Authors: Brian Baker, Barbara Schaeffler, Joe Hirman, Marcus Hompesch, Susan Pederson, Jeff Smith
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Endocrinology, Diabetes & Metabolism
Subjects:
eptinezumab
obesity
type 1 diabetes
Online Access:https://doi.org/10.1002/edm2.217

Similar Items

Similar Items